OTLK Stock Price, Outlook Therapeutics Inc Quote, Chart

Market Summary

USD7.79+0.46

Delayed

6.28%

OTLK Stock Price

View Fullscreen

OTLK RSI Chart

OTLK Valuation

Market Cap

182.3M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

21.35

EV/EBITDA

-0.86

Price/Free Cashflow

-3.13

OTLK Price/Sales (Trailing)

OTLK Profitability

EBT Margin

-1897.88%

Return on Equity

118.55%

Return on Assets

-269.59%

Free Cashflow Yield

-31.95%

OTLK Fundamentals

OTLK Revenue

Revenue (TTM)

8.1M

OTLK Earnings

Earnings (TTM)

-159.1M

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

-922.42%

Breaking Down OTLK Revenue

Last 7 days

2.8%

Last 30 days

-9.5%

Last 90 days

1631.1%

Trailing 12 Months

538.5%

How does OTLK drawdown profile look like?

OTLK Financial Health

Current Ratio

1.07

Debt/Equity

-0.09

Debt/Cashflow

-4.64

OTLK Investor Care

Shares Dilution (1Y)

82.38%

Diluted EPS (TTM)

-11.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	3.3M	3.1M	8.1M	0
2018	4.7M	5.2M	3.1M	3.4M
2017	1.6M	1.4M	3.8M	4.3M
2016	3.8M	3.0M	3.0M	2.3M
2015	7.8M	6.5M	5.2M	3.3M
2014	0	0	9.1M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Outlook Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	syntone ventures llc	bought	-	-	714,286	-
Mar 28, 2024	haddadin yezan munther	bought	22,241	11.82	1,881	-
Mar 18, 2024	sukhtian ghiath m.	acquired	-	-	2,305,710	-
Mar 07, 2024	evanson jeff	bought	26,243	0.42	62,484	chief commercial officer
Apr 20, 2023	dagnon terry	sold	-590,200	1.135	-520,000	chief operations officer
Jan 20, 2023	evanson jeff	sold	-296,370	1.11	-267,000	chief commercial officer
Jan 19, 2023	evanson jeff	sold	-125,971	1.22	-103,255	chief commercial officer
Jan 18, 2023	evanson jeff	sold	-42,172	1.25	-33,738	chief commercial officer
Jan 17, 2023	evanson jeff	sold	-35,582	1.31	-27,162	chief commercial officer
Dec 28, 2022	sukhtian ghiath m.	acquired	12,500,000	0.8784	14,230,400	-

Which funds bought or sold OTLK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	new	-	10,567	10,567	-%
May 16, 2024	Ancora Advisors LLC	new	-	72,834	72,834	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-20,836	-	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	161,763	161,763	-%
May 16, 2024	Ancora Advisors LLC	sold off	-100	-48,068	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	sold off	-100	-10,199	-	-%
May 15, 2024	Voya Investment Management LLC	sold off	-100	-11,995	-	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	new	-	19,335,800	19,335,800	2.01%
May 15, 2024	WEXFORD CAPITAL LP	sold off	-100	-19,188	-	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-85,000	-	-%

Are Funds Buying or Selling OTLK?

Are funds buying OTLK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OTLK

No. of Funds

Unveiling Outlook Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	syntone ventures llc	11.4%	2,776,867	SC 13D/A
Apr 08, 2024	great point partners llc	9.99%	2,231,324	SC 13G
Mar 28, 2024	velan capital investment management lp	5.6%	1,250,000	SC 13G
Mar 28, 2024	tang capital partners lp	9.99%	2,215,851	SC 13G
Mar 20, 2024	gms ventures & investments	37.0%	9,266,645	SC 13D/A
Jan 31, 2024	tenshi healthcare pte. ltd.	6.4%	16,637,024	SC 13D/A
Nov 29, 2023	tenshi healthcare pte. ltd.	7.4%	19,351,493	SC 13D/A
Feb 21, 2023	hope jason	7.8%	2e+07	SC 13G/A
Dec 29, 2022	gms ventures & investments	27.9%	71,277,519	SC 13D/A
Jul 08, 2022	tenshi healthcare pte. ltd.	10.2%	22,982,529	SC 13D/A

Recent SEC filings of Outlook Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 13, 2024	8-K	Current Report
May 06, 2024	EFFECT	EFFECT
May 06, 2024	424B3	Prospectus Filed
May 01, 2024	8-K	Current Report
Apr 26, 2024	S-3	S-3
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 16, 2024	D	D

Peers (Alternatives to Outlook Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Outlook Therapeutics Inc News

Latest updates

Outlook Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q3
Revenue	902.6%	6.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	3.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	0.00	1.00	0.00	-
Operating Expenses	197.8%	19.00	6.00	8.00	11.00	13.00	8.00	8.00	4.00	6.00	8.00	8.00	-	-	-	-	-	-	-	-	-
S&GA Expenses	51.7%	3.00	2.00	2.00	3.00	6.00	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	71.7%	7.00	4.00	6.00	6.00	7.00	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-80.6%	0.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-238.7%	-2.63	-0.78	-	-	-0.50	-	-	-3.15	0.00	-	-	0.00	-	500*	-	-	-	-	-	-
Earnings Before Taxes	-143.9%	-12.73	-5.22	-10.24	-9.74	-12.70	-8.43	-7.54	-5.07	-5.88	-5.33	-8.05	-	-	-	-	-	-	-	-	-
Net Income	-127.3%	-10.10	-4.44	-10.24	-9.74	-12.20	-8.43	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	172.2%	59.00	22.00	32.00	44.00	54.00	63.00	29.00	39.00	68.00	79.00	23.00	33.00	45.00	13.00	20.00	30.00	13.00	10.00	17.00	33.00	17.00
Current Assets	183.4%	58.00	20.00	31.00	43.00	53.00	62.00	28.00	38.00	67.00	77.00	22.00	32.00	44.00	11.00	18.00	28.00	9.00	7.00	14.00	19.00	2.00
Cash Equivalents	356.0%	47.00	10.00	23.00	34.00	44.00	52.00	17.00	26.00	58.00	70.00	14.00	20.00	37.00	6.00	13.00	24.00	5.00	1.00	8.00	14.00	0.00
Net PPE	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	3.00	14.00	15.00
Liabilities	319.9%	193	46.00	47.00	50.00	44.00	47.00	20.00	19.00	32.00	30.00	18.00	20.00	24.00	23.00	17.00	19.00	34.00	36.00	28.00	35.00	40.00
Current Liabilities	17.6%	54.00	46.00	47.00	50.00	44.00	15.00	20.00	18.00	31.00	20.00	7.00	20.00	24.00	12.00	16.00	18.00	24.00	20.00	20.00	23.00	27.00
Long Term Debt	-	-	-	-	-	-	-	-	-	13.00	12.00	-	-	-	-	-	-	-	-	0.00	0.00	0.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	1.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Shareholder's Equity	-451.4%	-134	-24.34	-14.44	-	10.00	16.00	9.00	20.00	36.00	49.00	5.00	13.00	21.00	-	3.00	11.00	-	-	-	-	-
Retained Earnings	-23.9%	-593	-479	-467	-454	-434	-427	-408	-394	-377	-357	-342	-329	-317	-304	-289	-279	-276	-271	-254	-244	-239
Additional Paid-In Capital	1.5%	459	452	451	447	442	441	415	412	411	404	346	340	336	292	291	290	255	240	238	238	212
Shares Outstanding	69.2%	22.00	13.00	13.00	13.00	13.00	11.00	11.00	10.00	10.00	9.00	9.00	8.00	7.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	180	-	-	-	222	-	-	-	200	-	-	-	20.00	-	-	-	19.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-47.8%	-19,267	-13,032	-12,741	-13,216	-8,114	-8,901	-10,250	-21,099	-14,334	-10,990	-8,990	-20,192	-11,746	-13,324	-12,077	-5,955	-7,083	-6,673	-5,942	-10,306	-6,259
Share Based Compensation	3.0%	1,311	1,273	1,389	1,382	1,383	1,392	1,376	1,368	3,763	1,204	1,405	1,198	1,130	1,155	785	1,359	305	359	205	-31.26	268
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1*	-150	-50.14
Cashflow From Financing	1763842.3%	56,140	-3.18	2,424	3,296	-597	43,845	1,626	-11,303	2,608	66,664	3,775	2,715	43,347	6,357	661	26,156	10,402	-8.29	-68.85	24,329	6,237

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OTLK Income Statement

2024-03-31

Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,508,934	$ 544,948	$ 18,038,292	$ 10,407,372
General and administrative	5,431,041	6,292,982	11,224,805	12,118,586
Total Operating expenses	18,939,975	6,837,930	29,263,097	22,525,958
Loss from operations	(18,939,975)	(6,837,930)	(29,263,097)	(22,525,958)
Loss (income) on equity method investment	30,595	16,965	28,047	(4,540)
Interest expense (income), net	3,084,035	(187,794)	2,895,358	2,260,797
Loss on extinguishment of debt				577,659
Change in fair value of promissory notes	8,519,153	3,000	9,512,153	3,000
Warrants related expenses (Note 9)	34,097,568		34,097,568
Change in fair value of warrant liability	49,614,817	(18,615)	49,668,159	(48,875)
Loss before income taxes	(114,286,143)	(6,651,486)	(125,464,382)	(25,313,999)
Income tax expense	2,800	2,800	2,800	2,800
Net loss	$ (114,288,943)	$ (6,654,286)	$ (125,467,182)	$ (25,316,799)
Per share information:
Net loss per share of common stock, basic (in dollars per share)	$ (8.01)	$ (0.52)	$ (9.20)	$ (2.09)
Net loss per share of common stock, diluted (in dollars per share)	$ (8.01)	$ (0.52)	$ (9.20)	$ (2.09)
Weighted average shares outstanding, basic (in shares)	14,270,289	12,833,330	13,638,126	12,093,889
Weighted average shares outstanding, diluted (in shares)	14,270,289	12,833,330	13,638,126	12,093,889

OTLK Balance Sheet

2024-03-31

Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 47,229,109	$ 23,391,982
Prepaid expenses and other current assets	10,556,696	7,587,216
Total current assets	57,785,805	30,979,198
Operating lease right-of-use assets, net	3,739	26,172
Equity method investment	765,885	793,932
Other assets	473,241	501,299
Total assets	59,028,670	32,300,601
Current liabilities:
Unsecured convertible promissory note	44,745,000	35,551,000
Finance lease liabilities		4,267
Accounts payable	4,363,235	6,574,523
Accrued expenses	3,115,390	2,745,740
Income taxes payable	1,856,629	1,856,629
Total current liabilities	54,080,254	46,732,159
Warrant liability	139,184,543	6,219
Total liabilities	193,264,797	46,738,378
Commitments and contingencies (Note 8)
Convertible preferred stock:
Total convertible preferred stock
Stockholders' deficit:
Preferred stock, value
Common stock, par value $0.01 per share; 60,000,000 shares authorized; 22,012,827 and 13,012,833 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively	220,128	130,128
Additional paid-in capital	458,929,113	453,350,281
Accumulated deficit	(593,385,368)	(467,918,186)
Total stockholders' deficit	(134,236,127)	(14,437,777)
Total liabilities, convertible preferred stock and stockholders' deficit	59,028,670	32,300,601
Series A convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series A-1 convertible preferred stock
Convertible preferred stock:
Total convertible preferred stock
Series B convertible preferred stock
Stockholders' deficit:
Preferred stock, value

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

CEO	Mr. C. Russell Trenary III
WEBSITE	outlooktherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	17

Outlook Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Outlook Therapeutics Inc? What does OTLK stand for in stocks?

OTLK is the stock ticker symbol of Outlook Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Outlook Therapeutics Inc (OTLK)?

As of Fri May 17 2024, market cap of Outlook Therapeutics Inc is 182.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OTLK stock?

You can check OTLK's fair value in chart for subscribers.

What is the fair value of OTLK stock?

You can check OTLK's fair value in chart for subscribers. The fair value of Outlook Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Outlook Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OTLK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Outlook Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether OTLK is over valued or under valued. Whether Outlook Therapeutics Inc is cheap or expensive depends on the assumptions which impact Outlook Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OTLK.

What is Outlook Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, OTLK's PE ratio (Price to Earnings) is -1.15 and Price to Sales (PS) ratio is 21.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OTLK PE ratio will change depending on the future growth rate expectations of investors.